|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients.
|
12174914 |
2002 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These data suggest that SEMA3C expression is differentially regulated in the development and progression of breast versus oral neoplasia, and that increased expression of SEMA3C may be modulating breast cancer progression and angiogenesis, and could represent a biomarker of metastatic disease.
|
25910410 |
2015 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Inhibition of SEMA3C reduces adhesion and invasion of breast cancer cells.
|
26977026 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our experiments showed that Sema3C not only affects angiogenesis of CAM by inhibiting neovascularization but also acts as an anti-tumorigenic molecule by hampering U87 MG cell invasion into mesenchyme.
|
31726800 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In addition, we show that SEMA3C promotes migration and invasion in vitro and cell dissemination in vivo.
|
28904399 |
2017 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Inhibition of SEMA3C reduces adhesion and invasion of breast cancer cells.
|
26977026 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemistry of human samples revealed that sema3C was strongly expressed in neoplastic cells, especially at the invasion front.
|
22924992 |
2012 |
|
Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis was used for detection of Sema3C protein levels in 84 different grade glioma samples: 12 grade I astrocytomas, 30 grade II astrocytomas, 17 grade III astrocytomas, and 25 grade IV astrocytomas (glioblastomas).
|
26032848 |
2015 |
|
Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
One family member, Semaphorin 3 C (SEMA3C), has been implicated in prostate, breast, ovarian, gastric, lung, and pancreatic cancer as well as glioblastoma.
|
28904399 |
2017 |
|
Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our studies suggest that Sema3C could be a promising target for glioblastoma treatment.
|
31726800 |
2019 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Previous studies have suggested that semaphorin 3C (SEMA3C) is involved in the tumorigenesis and metastasis of a number of types of cancer.
|
29113226 |
2017 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of sema3c attenuated proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) in a pancreatic cancer cell line and reduced PDAC cell tumorigenesis upon xenotransplantation into NOD/SCID mice.
|
28315433 |
2017 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Recent studies suggested involvement of Sema3C (semaphorin 3C) protein in tumorigenesis and metastasis in a number of cancers.
|
26032848 |
2015 |
|
Endometriosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Reduced Sympathetic Innervation in Endometriosis is Associated to Semaphorin 3C and 3F Expression.
|
27558236 |
2017 |
|
Endometriosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Group 2 genes are normally down-regulated during the window of implantation but are significantly increased with endometriosis: semaphorin E, neuronal olfactomedin-related endoplasmic reticulum localized protein mRNA and Sam68-like phosphotyrosine protein alpha.
|
12810542 |
2003 |
|
Glioma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Further, all glioma cell lines express SEMA3A and SEMA3C and exhibit SEMA3A binding sites.
|
12730958 |
2003 |
|
Glioma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis was used for detection of Sema3C protein levels in 84 different grade glioma samples: 12 grade I astrocytomas, 30 grade II astrocytomas, 17 grade III astrocytomas, and 25 grade IV astrocytomas (glioblastomas).
|
26032848 |
2015 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our studies suggest that Sema3C could be a promising target for glioblastoma treatment.
|
31726800 |
2019 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
One family member, Semaphorin 3 C (SEMA3C), has been implicated in prostate, breast, ovarian, gastric, lung, and pancreatic cancer as well as glioblastoma.
|
28904399 |
2017 |
|
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our studies suggest that Sema3C could be a promising target for glioblastoma treatment.
|
31726800 |
2019 |
|
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
One family member, Semaphorin 3 C (SEMA3C), has been implicated in prostate, breast, ovarian, gastric, lung, and pancreatic cancer as well as glioblastoma.
|
28904399 |
2017 |
|
Hormone refractory prostate cancer
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, all of EGFR, JAK2, NR3C1, PDZD2, and SEMA3C genes had single nucleotide polymorphisms (SNP) in castration-resistant prostate cancer, consistent with high selection pressure on these genes during drug treatment and consequent resistance.
|
30644608 |
2019 |
|
Hormone refractory prostate cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration <i>in vivo</i> SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.
|
29348142 |
2018 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our studies suggest that Sema3C could be a promising target for glioblastoma treatment.
|
31726800 |
2019 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
One family member, Semaphorin 3 C (SEMA3C), has been implicated in prostate, breast, ovarian, gastric, lung, and pancreatic cancer as well as glioblastoma.
|
28904399 |
2017 |